02268.HK
WuXi XDC Cayman Inc
HKSE · Healthcare · Medical - Diagnostics & Research · CN
HKD 72.80
−0.41%Year over year
Reported trailing growth
- Revenue
- +169.2%
- EBITDA
- +280.4%
- EBIT
- +297.1%
- EPS
- +225.0%
- Free cash flow
- +160.5%
- Operating cash flow
- +1233.5%
Forward estimates
Based on analyst estimates
- Revenue
- +23.4%
- EBITDA
- +63.5%
- EPS
- +37.4%
Three-year CAGR
- Revenue
- +81.7%
- EBITDA
- +126.6%
- EBIT
- +134.4%
- Net income
- +111.8%
- EPS
- +110.9%
- Free cash flow
- +132.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026